BeiGene Total Assets 2014-2024 | ONC
BeiGene total assets from 2014 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
- BeiGene total assets for the quarter ending September 30, 2024 were $5.831B, a 5.54% increase year-over-year.
- BeiGene total assets for 2023 were $5.805B, a 9% decline from 2022.
- BeiGene total assets for 2022 were $6.379B, a 25.26% decline from 2021.
- BeiGene total assets for 2021 were $8.536B, a 52.4% increase from 2020.
BeiGene Annual Total Assets
(Millions of US $) |
| 2023 |
$5,805 |
| 2022 |
$6,379 |
| 2021 |
$8,536 |
| 2020 |
$5,601 |
| 2019 |
$1,612 |
| 2018 |
$2,250 |
| 2017 |
$1,046 |
| 2016 |
$406 |
| 2015 |
$117 |
| 2014 |
$54 |
| 2013 |
$0 |
BeiGene Quarterly Total Assets
(Millions of US $) |
| 2024-09-30 |
$5,831 |
| 2024-06-30 |
$5,712 |
| 2024-03-31 |
$5,668 |
| 2023-12-31 |
$5,805 |
| 2023-09-30 |
$5,525 |
| 2023-06-30 |
$5,729 |
| 2023-03-31 |
$5,957 |
| 2022-12-31 |
$6,379 |
| 2022-09-30 |
$6,726 |
| 2022-06-30 |
$7,378 |
| 2022-03-31 |
$8,021 |
| 2021-12-31 |
$8,536 |
| 2021-09-30 |
$5,286 |
| 2021-06-30 |
$5,524 |
| 2021-03-31 |
$5,821 |
| 2020-12-31 |
$5,601 |
| 2020-09-30 |
$5,566 |
| 2020-06-30 |
$3,903 |
| 2020-03-31 |
$4,067 |
| 2019-12-31 |
$1,612 |
| 2019-09-30 |
$1,881 |
| 2019-06-30 |
$2,150 |
| 2019-03-31 |
$2,172 |
| 2018-12-31 |
$2,250 |
| 2018-09-30 |
$2,409 |
| 2018-06-30 |
$1,654 |
| 2018-03-31 |
$1,709 |
| 2017-12-31 |
$1,046 |
| 2017-09-30 |
$1,049 |
| 2017-06-30 |
$474 |
| 2017-03-31 |
$377 |
| 2016-12-31 |
$406 |
| 2016-09-30 |
$235 |
| 2016-06-30 |
$251 |
| 2016-03-31 |
$265 |
| 2015-12-31 |
$117 |
| 2015-06-30 |
$0 |
| 2015-03-31 |
$0 |
| 2014-12-31 |
$54 |
| 2013-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
